Amedeo Smart

Free Medical Literature Service



Alzheimer's Disease

  Free Subscription

Articles published in
    April 2022
  1. DHANA K, Franco OH, Ritz EM, Ford CN, et al
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ. 2022;377:e068390.
    >> Share

    March 2022
  2. DYER O
    Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
    BMJ. 2022;376:o808.
    >> Share

    January 2022
  3. LYTHGOE MP, Jenei K, Prasad V
    Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    BMJ. 2022;376:e069780.
    >> Share

    December 2021
    Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
    BMJ. 2021;375:n3127.
    >> Share

    November 2021
  5. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    >> Share

    September 2021
  6. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    >> Share

    August 2021
  7. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    >> Share

    July 2021
  8. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    >> Share

  9. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    >> Share

    June 2021
  10. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    >> Share

  11. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    >> Share

    February 2021
  12. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    >> Share

    October 2020
  13. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    >> Share

    December 2019
  14. JOE E, Ringman JM
    Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    BMJ. 2019;367:l6217.
    >> Share

    October 2019
  15. HAWKES N
    FDA considers Alzheimer's drug previously abandoned for lack of effectiveness.
    BMJ. 2019;367:l6164.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016